» Authors » Manon M-J Couture

Manon M-J Couture

Explore the profile of Manon M-J Couture including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 433
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shapiro J, Andreani G, Dube C, Berube M, Bussiere D, Couture M, et al.
Vaccine . 2023 Aug; 41(41):6008-6016. PMID: 37625992
Background: Norovirus (NoV) is the most common cause of diarrheal episodes globally. Issues with in vitro cultivation systems, genetic variation, and animal models have hindered vaccine development. Plant-derived virus-like particles...
2.
Kurokawa N, Robinson M, Bernard C, Kawaguchi Y, Koujin Y, Koen A, et al.
Vaccine . 2021 Aug; 39(39):5513-5523. PMID: 34454786
Background: This study is the first clinical trial for a parenteral non-replicating rotavirus vaccine developed using virus-like particle (VLP) technology. Methods: This open-labeled, randomized, placebo-controlled trial was conducted in two...
3.
Kurokawa N, Lavoie P, DAoust M, Couture M, Dargis M, Trepanier S, et al.
Vaccine . 2021 Jul; 39(35):4979-4987. PMID: 34325930
Background: Virus-like particles (VLPs) are unable to replicate in the recipient but stimulate the immune system through recognition of repetitive subunits. Parenterally delivered rotavirus-VLP (Ro-VLP) vaccine could have the potential...
4.
Le Mauff F, Loutelier-Bourhis C, Bardor M, Berard C, Doucet A, DAoust M, et al.
Plant Biotechnol J . 2016 Aug; 15(3):285-296. PMID: 27483398
Influenza virus-like particles (VLPs) have been shown to induce a safe and potent immune response through both humoral and cellular responses. They represent promising novel influenza vaccines. Plant-based biotechnology allows...
5.
Young K, Arthus-Cartier G, Yam K, Lavoie P, Landry N, DAoust M, et al.
FASEB J . 2015 Jun; 29(9):3817-27. PMID: 26038124
Medicago, Inc. has developed an efficient virus-like particle (VLP) vaccine production platform using the Nicotiana benthamiana expression system, and currently has influenza-based products targeting seasonal/pandemic hemagglutinin (HA) proteins in advanced...
6.
Jutras P, DAoust M, Couture M, Vezina L, Goulet M, Michaud D, et al.
Biotechnol J . 2015 Apr; 10(9):1478-86. PMID: 25914077
Eukaryotic expression systems are used for the production of complex secreted proteins. However, recombinant proteins face considerable biochemical challenges along the secretory pathway, including proteolysis and pH variation between organelles....
7.
DAoust M, Couture M, Charland N, Trepanier S, Landry N, Ors F, et al.
Plant Biotechnol J . 2010 Mar; 8(5):607-19. PMID: 20199612
During the last decade, the spectre of an influenza pandemic of avian origin has led to a revision of national and global pandemic preparedness plans and has stressed the need...
8.
DAoust M, Lavoie P, Couture M, Trepanier S, Guay J, Dargis M, et al.
Plant Biotechnol J . 2008 Dec; 6(9):930-40. PMID: 19076615
A strain-specific vaccine represents the best possible response to the threat of an influenza pandemic. Rapid delivery of such a vaccine to the world's population before the peak of the...
9.
Brown E, Friemann R, Karlsson A, Parales J, Couture M, Eltis L, et al.
J Biol Inorg Chem . 2008 Aug; 13(8):1301-13. PMID: 18719951
The Rieske iron-sulfur proteins have reduction potentials ranging from -150 to +400 mV. This enormous range of potentials was first proposed to be due to differing solvent exposure or even...
10.
Couture M, Martin V, Mohn W, Eltis L
Biochim Biophys Acta . 2006 Sep; 1764(9):1462-9. PMID: 16952485
DitA3, a small soluble ferredoxin, is a component of a ring-hydroxylating dioxygenase involved in the microbial degradation of the diterpenoid, dehydroabietic acid. The anaerobic purification of a heterologously expressed his-tagged...